NCT07482566Recruiting
Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer
A Multicenter Prospective Randomized Double-Blind Clinical Trial Comparing Proximal Gastrectomy and Total Gastrectomy in Patients With Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
This multicenter prospective randomized clinical trial aims to compare the safety and oncological effectiveness of proximal gastrectomy and total gastrectomy in patients with locally advanced Siewert type II-III gastroesophageal junction cancer. Eligible patients will be randomly assigned to undergo either proximal gastrectomy or total gastrectomy using open, laparoscopic, or robotic surgical approaches according to clinical suitability. The primary outcome of the study is 3-year disease-free survival. Secondary outcomes include postoperative mortality, postoperative complications, and the number of metastatic lymph nodes retrieved. Patients will be followed for up to five years after surgery to evaluate long-term oncological outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 15 Mar 2026
- Start date
- 1 Feb 2026
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- Nurettin Şahin
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07482566
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 1 Feb 2026 to the primary completion date, 1 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Early-stage gastroesophageal junction cancer
- Gastric cancers located in the antrum or corpus
Other
- Severe anesthetic risk (American Society of Anesthesiologists \[ASA\] class IV or higher)
- Pregnancy
- Patients unwilling or unable to provide informed consent
Who the study is looking for
- Age between 18 and 90 years
- Histologically confirmed locally advanced Siewert type II-III gastroesophageal junction cancer
- Considered operable after multidisciplinary tumor board evaluation
- Candidate for curative surgical resection with D2 lymphadenectomy
- Provision of written informed consent
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bakirkoy Dr. Sadi Konuk Training and Research Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.